- A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysis
- Neurofilament biomarker results from Biogen collaboration expected in January 2024
- Primary biomarker endpoints, TDP-43 and Prostagladin2, are expected in H1 2024
- PrimeC’s meaningful effect magnitude, strong safety profile, and unique mechanism of action will be discussed with the FDA and other regulatory agencies in an End of Phase 2 meeting in H1 2024
